PTC299

Known as: VEGF Inhibitor PTC299 
An orally bioavailable, small molecule inhibitor of vascular endothelial growth factor (VEGF) synthesis with potential antiangiogenesis and… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2016
012320112016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
PTC299 is a novel small molecule that specifically blocks the production of protein from selected mRNAs that under certain… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2016
2016
Vascular endothelial growth factor (VEGF) plays an important role in Kaposi's sarcoma (KS). We administered PTC299, a post… (More)
Is this relevant?
2014
2014
PTC299 is a novel, orally-bioavailable small molecule that selectively inhibits vascular endothelial growth factor receptor… (More)
  • figure 1
  • table 1
  • table 3
  • table 2
  • figure 2
Is this relevant?
2011
2011
3069 Background: Antiangiogenic drugs interfere with the VEGF signaling pathway. PTC299, an oral investigational drug, is… (More)
Is this relevant?
2011
2011
1100 Background: PTC299, an oral investigational drug, suppresses tumor growth by selective posttranscriptional inhibition of… (More)
Is this relevant?
Review
2011
Review
2011
Vestibular schwannomas are histopathologically benign tumors arising from the Schwann cell sheath surrounding the vestibular… (More)
Is this relevant?